Primary Sjögren's syndrome (pSS) has multi-dimensional manifestations, including neutropenia and polyneuropathy. We herein report a 76-year-old woman with pSS initially presenting as severe granulocyte-colony-stimulating factor (G-CSF)-refractory neutropenia and axonal sensorimotor polyneuropathies (SMP). Systemic glucocorticoid administration had reduced neutrophil-associated immunoglobulin G (NAIgG) on the neutrophil surface as detected using flow cytometry, resulting in the development of neutropenia. A patient with pSS concomitant with axonal SMP might show severe neutropenia as aggressive autoimmune disease. Neutropenia can be treated with systemic glucocorticoids based on the assessment of NAIgG on the neutrophil surface.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683808 | PMC |
http://dx.doi.org/10.2169/internalmedicine.9092-21 | DOI Listing |
Expert Opin Drug Saf
December 2024
Department of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Background: Panitumumab has been extensively applied in antitumor therapy, and the regulation of its adverse drug reactions (ADRs) has become extremely important. This study utilized the U.S.
View Article and Find Full Text PDFNeurohospitalist
October 2024
Department of Neurology, University Hospital "12 de Octubre", Madrid, Spain.
Curr Opin Oncol
September 2024
University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD).
Purpose Of Review: Hodgkin lymphoma (HL) occurs at two age peaks around 25 and 60 years of age. Due to varying fitness and co-morbidities older patients are a heterogeneous group that has relatively poor treatment outcomes. The evolving therapeutic landscape for older HL is summarized herein.
View Article and Find Full Text PDFFront Oncol
June 2024
Department of Obstetrics and Gynecology, Breast Center and Comprehensive Cancer Center (CCC) Munich, University Hospital, LMU Munich, Munich, Germany.
Background: Since the European approval of CDK4/6 inhibitors in 2016, the treatment of patients with hormone-receptor-positive, HER2-negative metastatic breast cancer has changed significantly. Compared with chemotherapy, endocrine-based therapy has different treatment regimens and is associated with new side effects. Oral therapy aims for optimal drug efficacy and long treatment times while maintaining maximum independence and quality of life resulting in the conservation of medical staff resources.
View Article and Find Full Text PDFBr J Haematol
August 2024
Department of Hematology, Myeloma and Lymphoma Center, Changzheng Hospital, Shanghai, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!